Cat. No. 2601
Chemical Name: 17-(Cyclopropylmethyl)-4,14-dimetho
Biological ActivitySelective μ-opioid receptor antagonist (Ki values are 5.4, 244.6 and 2187 nM for μ-, δ- and κ-opioid receptors respectively). Reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Henry et al (2001) μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp.Neurol. 171 139. PMID: 11520128.
Marki et al (1999) μ-opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγs binding assays. Eur.J.Pharmacol. 383 209. PMID: 10585536.
Schmidhammer et al (1995) Synthesis and biological evaluation of 14-alkoxymorphinans. 11. 3-hydroxycyprodime and analogues: opioid antagonist profile in comparison to cyprodime. J.Med.Chem. 38 3071. PMID: 7636870.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Cyprodime hydrochloride include:
Lee et al (2012) Prostatic relaxation induced by loperamide is reduced in spontaneously hypertensive rats. J Neurosci 2012 941685. PMID: 22645476.
Do you know of a great paper that uses Cyprodime hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Cyprodime hydrochloride, supplier, Selective, μ-opioid, mu-opioid, antagonists, MOP, Receptors, OP3, Tocris Bioscience, μ Opioid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Fluorescent opioid antagonist; fluorescent-derivative of naloxone (Cat. No. 0599)BMS 986187
Potent δ-opioid receptor positive allosteric modulator
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.